{"created":"2023-06-20T15:56:55.160893+00:00","id":13992,"links":{},"metadata":{"_buckets":{"deposit":"1a44aa53-2057-45ce-bc0e-b036438e9be2"},"_deposit":{"created_by":53,"id":"13992","owners":[53],"pid":{"revision_id":0,"type":"depid","value":"13992"},"status":"published"},"_oai":{"id":"oai:redcross.repo.nii.ac.jp:00013992","sets":["615:616:617"]},"author_link":["50708","50706","50705","50709","50707"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2018-11","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"33","bibliographicPageStart":"26","bibliographicVolumeNumber":"29","bibliographic_titles":[{"bibliographic_title":"岡山赤十字病院医学雑誌"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"当院における過去3年間の免疫抑制・化学療法によるB型肝炎ウイルス(HBV)再活性化を検討した。2015年1月〜2017年12月に抗癌剤プロトコールに登録された2,105例(固形癌1,848例、血液腫瘍257例)、自己免疫疾患に対して免疫抑制剤を投与された845例、計2,950例中7例(0.24%)でHBV再活性化を認めた。1例はHBs抗原陽性、6例は既往感染例だった。抗癌剤2,105例中HBV再活性化は2例で、いずれも悪性リンパ腫(R-CHOPリツキシマブ、シクロフォスファミド、ドキソルビシン、ビンクリスチン、プレドニゾロン)だった。自己免疫疾患845例中5例でHBV再活性化を認め、関節リウマチ3例(アバタセプト、サラゾスルファピリジン、メトトレキサート)、強皮症1例(シクロフォスファミド)、膿疱性乾癬1例(セクキヌマブ)だった。7例とも核酸アナログ投与により再活性化に伴う肝炎の発生は予防された。(著者抄録)","subitem_description_type":"Abstract"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"岡山赤十字病院"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0915-8073","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小橋, 春彦"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"歳森, 淳一"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"小山, 芳伸"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"藤井, 総一郎"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"竹内, 誠"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2019-03-14"}],"displaytype":"simple","filename":"03-3　原著 小橋 p.26-33.pdf","filesize":[{"value":"2.8 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"okayama000005","url":"https://redcross.repo.nii.ac.jp/record/13992/files/03-3　原著 小橋 p.26-33.pdf"},"version_id":"1e48d67b-de2a-423c-8298-a94001dc4545"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"HBV reactivation","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"de novo hepatitis B","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"chemotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"immunosuppressive","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"当院における過去3年間の免疫抑制・化学療法によるB型肝炎ウイルス再活性化の実態","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"当院における過去3年間の免疫抑制・化学療法によるB型肝炎ウイルス再活性化の実態"}]},"item_type_id":"10001","owner":"53","path":["617"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-03-14"},"publish_date":"2019-03-14","publish_status":"0","recid":"13992","relation_version_is_last":true,"title":["当院における過去3年間の免疫抑制・化学療法によるB型肝炎ウイルス再活性化の実態"],"weko_creator_id":"53","weko_shared_id":-1},"updated":"2023-06-20T18:49:20.501531+00:00"}